# Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer

> **NCT00019539** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)**

## Conditions studied

- Stage IV Renal Cell Cancer
- Recurrent Renal Cell Cancer

## Interventions

- **DRUG:** bevacizumab
- **DRUG:** thalidomide

## Key facts

- **NCT ID:** NCT00019539
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-11
- **Primary completion:** —
- **Final completion:** 2004-11
- **Target enrollment:** — (—)
- **Last updated:** 2024-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00019539

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00019539, "Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer". Retrieved via AI Analytics 2026-09-16 from https://api.ai-analytics.org/clinical/NCT00019539. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*